Louie Pasculli

Experimental small molecule CN045 promoted oligodendrocyte maturation and modest remyelination in preclinical models of multiple sclerosis, supporting further development of the compound as a potential remyelination therapy.

Voyager Therapeutics is advancing 2 tau-targeted Alzheimer disease therapies toward key clinical milestones expected in the fourth quarter of 2026, including tau PET imaging data for VY7523 and first-in-human dosing for VY1706.

Uma Menon, MD, Adult Neurology Residency Program Director at Allina Health, shares lessons on navigating fellowship, finding the right career path, building expertise, and maintaining balance throughout a career in neurology.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Spinal Muscular Atrophy!

Topline findings from the Phase 2 SUNRISE-PD study showed statistically significant improvements in clinical measures, inflammatory biomarkers, and exploratory neurodegeneration markers among patients with early Parkinson disease treated with bezisterim.

New phase 1 data showed favorable pharmacokinetic and safety findings for the investigational orexin-2 receptor agonist BP-205, supporting continued clinical development.

Neurologist Takaomi Saido, PhD, discusses decades of research into the neprilysin-donanemab and amyloid-beta–tau axes in Alzheimer disease, highlighting potential mechanisms underlying the transition from amyloid to tau pathology and opportunities to develop earlier, more targeted disease-modifying therapies.

Elizabeth Ferluga, MD, and Kristen Fortino discuss a newly launched virtual care program, the barriers facing patients with ataxia, and the potential for remote access to specialized care to improve diagnosis, treatment, and clinical trial connectivity.

As research expands beyond amyloid and tau, experts discuss how novel biomarkers could identify multiple coexisting neurodegenerative pathologies and pave the way for more personalized treatment approaches based on each patient’s unique disease profile. [WATCH TIME: 9 Minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is chronobiology in neurology!

As research moves toward treating Alzheimer disease before symptoms emerge, experts highlight the potential of plasma biomarkers to identify at-risk individuals, guide clinical trial enrollment, and create a window for intervention before irreversible neuronal damage occurs. [WATCH TIME: 6 Mintes]

Updated phase 2 data showed durable responses and sustained disease control with safusidenib after nearly 40 months of follow-up, prompting plans for phase 3 and phase 2 studies in newly diagnosed and post-vorasidenib IDH1-mutant glioma.

Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

The Trojanowski Professor for Neurodegenerative Disease Research at the University of Pennsylvania, discusses how postmortem and longitudinal imaging findings provide new insights into the potential downstream effects of amyloid clearance on tau pathology and neurodegeneration in Alzheimer disease. [WATCH TIME: 3 Mintutes]

Postmortem analyses of 8 individuals with SOD1-ALS who received tofersen showed widespread drug distribution across somatic motor system tissues and reductions of up to 84% in lumbar spinal cord SOD1 protein levels.

The professor of neurosciences and head of neuropsychology at Fleni Institute in Buenos Aires, Argentina, discussed findings from the LatAm-FINGERS study that suggest structured, multidomain lifestyle interventions may offer meaningful cognitive benefits among older adults in Latin America. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is tau-targeting therapies for Alzheimer disease!

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

At AAIC 2026, the head of sciences at the Alzheimer Center Amsterdam, discusses the growing role of biomarkers in understanding the biological complexity of Alzheimer disease and advancing more personalized approaches to diagnosis and treatment. [WATCH TIME: 3 minutes]

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

In a single-center retrospective analysis, approximately two-thirds of patients with treatment-refractory headache disorders reported improvement with off-label suzetrigine, supporting further prospective evaluation of the selective NaV1.8 inhibitor.

In the largest study of its kind, researchers examined the potential neurological effects of repetitive head impacts in retired elite soccer players, with findings offering new insights into symptoms, brain structure, and future research directions. [WATCH TIME: 3 Minutes]

Post hoc analyses from the phase 3 GRADUATE program suggest higher baseline tau pathology may limit amyloid removal with gantenerumab, offering new insight into factors that could influence response to anti-amyloid therapy.

In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a standalone diagnostic biomarker.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is RNA-targeted therapeutics

Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is retinal biomarkers for central nervous system disease!

New phase 2b PARADIGM data showed PrimeC significantly reduced neuron-derived TDP-43 levels in patients with ALS while reinforcing previously reported improvements in disease progression and survival.